PMID- 35915771
OWN - NLM
STAT- MEDLINE
DCOM- 20220803
LR  - 20220803
IS  - 1748-6718 (Electronic)
IS  - 1748-670X (Print)
IS  - 1748-670X (Linking)
VI  - 2022
DP  - 2022
TI  - Effects of Roflumilast on Patients with Chronic Obstructive Pulmonary Disease 
      Treated with Inhaled Corticosteroid/Long-Acting beta2 Agonist: A Meta-analysis.
PG  - 8101099
LID - 10.1155/2022/8101099 [doi]
LID - 8101099
AB  - OBJECTIVE: Roflumilast is a novel therapeutic drug for chronic obstructive 
      pulmonary disease (COPD). This study was designed to evaluate the efficacy and 
      safety of roflumilast combining inhaled corticosteroid (ICS)/long-acting beta2 
      agonist (LABA) in treating COPD patients through the meta-analysis. METHODS: 
      Randomized controlled trials of roflumilast combining ICS/LABA in treating 
      patients with severe and profound COPD were searched from PubMed, Cochrane 
      Library, and Embase databases from their establishment to February 2022. The 
      quality of included studies was assessed by Cochrane risk bias assessment tool. 
      The main outcomes of these studies should include at least one of the following 
      clinical outcome indicators: forced expiratory volume in one second (FEV(1)), 
      exacerbation rate, and adverse events (AEs) such as diarrhea, nasopharyngitis, 
      and headache. RESULTS: Six articles were included in the study, including 9,715 
      patients. Meta-analysis revealed that compared with placebo, roflumilast gained 
      superiority for severe COPD patients treated with ICS/LABA combinations in FEV(1) 
      before bronchodilator administration (MD = 46.62, 95% CI (30.69, 62.55), P < 
      0.00001), FEV(1) after bronchodilator administration (MD = 45.62, 95% CI (34.95, 
      56.28), P < 0.00001), and COPD exacerbation rate (RR = 0.90, 95% CI (0.87, 0.94), 
      P = 0.001). In terms of safety, the incidence of diarrhea, headache, nausea, 
      weight loss, back pain, loss of appetite, and insomnia was notably higher in the 
      roflumilast group than in the placebo group. CONCLUSION: Roflumilast is suggested 
      to be significantly effective for severe COPD patients with ICS/LABA combination 
      therapy, which reduces the exacerbation rate but also leads to PDE4 
      inhibitor-related adverse reactions.
CI  - Copyright (c) 2022 Shasha Zeng et al.
FAU - Zeng, Shasha
AU  - Zeng S
AUID- ORCID: 0000-0002-2407-7171
AD  - Department of Internal Medicine, Chongqing Nanan Traditional Chinese Medicine 
      Hospital, Chongqing 400060, China.
FAU - Bai, Haibing
AU  - Bai H
AUID- ORCID: 0000-0003-1441-7483
AD  - Department of Internal Medicine, Chongqing Nanan Traditional Chinese Medicine 
      Hospital, Chongqing 400060, China.
FAU - Zou, Mi
AU  - Zou M
AUID- ORCID: 0000-0001-6501-0179
AD  - Respiratory Department, The First Branch of the First Affiliated Hospital of 
      Chongqing Medical University, Chongqing 400015, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20220723
PL  - United States
TA  - Comput Math Methods Med
JT  - Computational and mathematical methods in medicine
JID - 101277751
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Adrenergic beta-2 Receptor Agonists)
RN  - 0 (Aminopyridines)
RN  - 0 (Benzamides)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Cyclopropanes)
RN  - 0P6C6ZOP5U (Roflumilast)
SB  - IM
MH  - Adrenal Cortex Hormones/adverse effects
MH  - Adrenergic beta-2 Receptor Agonists/adverse effects
MH  - Aminopyridines
MH  - Benzamides
MH  - *Bronchodilator Agents/adverse effects
MH  - Cyclopropanes
MH  - Diarrhea/chemically induced/drug therapy
MH  - Disease Progression
MH  - Headache/chemically induced/drug therapy
MH  - Humans
MH  - *Pulmonary Disease, Chronic Obstructive/drug therapy
PMC - PMC9338846
COIS- The authors declare that they have no conflicts of interest with the contents of 
      this article.
EDAT- 2022/08/03 06:00
MHDA- 2022/08/04 06:00
PMCR- 2022/07/23
CRDT- 2022/08/02 01:49
PHST- 2022/04/26 00:00 [received]
PHST- 2022/06/23 00:00 [revised]
PHST- 2022/06/27 00:00 [accepted]
PHST- 2022/08/02 01:49 [entrez]
PHST- 2022/08/03 06:00 [pubmed]
PHST- 2022/08/04 06:00 [medline]
PHST- 2022/07/23 00:00 [pmc-release]
AID - 10.1155/2022/8101099 [doi]
PST - epublish
SO  - Comput Math Methods Med. 2022 Jul 23;2022:8101099. doi: 10.1155/2022/8101099. 
      eCollection 2022.